Jamal Aisha, Khan Mohammad Tahir, Parveen Sadia, Rizvi Qurratulain, Farzana Tasneem, Zaidi Uzma, Borhany Munira, Siddiqui Saima, Ansari Saqib Hussain, Shamsi Tahir Sultan
Clinical Haematology, National Institute of Blood Disease and Bone Marrow Transplantation, ST, 2/A Block 17 Gulshan-e-Iqbal KDA Scheme 24, Karachi, 75300, Pakistan.
School of Public Health, Dow University of Health Sciences, 111 Suparco Rd, Gulzar-e-Hijri Gulzar E Hijri Scheme 33, Karachi, Karachi, City, Sindh, Pakistan.
Transl Oncol. 2020 Jul;13(7):100788. doi: 10.1016/j.tranon.2020.100788. Epub 2020 May 11.
We assessed the predictive potential of XN-HPC for CD34+ cell count as obtained through Sysmex automated hematology analyzers (XN-1000).
This study was conducted at the National Institute of Blood Diseases and Bone Marrow Transplantation in 84 donors between December 2012 and December 2017 in the first phase and later validated in 112 donors between December 2017 and December 2018. Sysmex XN-1000 and BD FACS Calibur estimated XN-HPC and CD34+ cells of peripheral blood apheresis product, respectively. Spearman's correlation was assessed between XN-HPC and CD34+ cell count followed by receiver operating characteristic curve calculation to determine the XN-HPC cutoff for a CD34+ count of ≥2 million cells/kg of recipient's body weight RESULTS: There is a moderately positive correlation (P value = .003) between XN-HPC and CD34+ count. Receiver operating characteristic curve analyses demonstrated that a cutoff value for XN-HPC of ≥1·845×10cells/kg of recipient's body weight has a specificity and sensitivity of 100% and 78·2%, respectively, for predicting the CD34+ count of ≥2 million cells/kg of recipient's body weight. This cutoff value of XN-HPC was prospectively validated in 112 donors. The positive predictive value was found to be 100%, while negative predictive value was 17%.
XN-HPC has a highly promising potential to serve as a cost-effective and time-saving surrogate for CD34+ cell count.
我们评估了XN-HPC对于通过Sysmex自动血液分析仪（XN-1000）获得的CD34+细胞计数的预测潜力。
本研究于2012年12月至2017年12月在国家血液疾病和骨髓移植研究所对84名供者进行了第一阶段研究，随后于2017年12月至2018年12月在112名供者中进行了验证。Sysmex XN-1000和BD FACS Calibur分别用于估计外周血单采产品中的XN-HPC和CD34+细胞。评估XN-HPC与CD34+细胞计数之间的Spearman相关性，随后计算受试者工作特征曲线，以确定CD34+计数≥200万个细胞/受体体重千克时的XN-HPC临界值。结果：XN-HPC与CD34+计数之间存在中度正相关（P值=0.003）。受试者工作特征曲线分析表明，XN-HPC临界值≥1.845×10细胞/受体体重千克时，对于预测CD34+计数≥200万个细胞/受体体重千克的特异性和敏感性分别为100%和78.2%。XN-HPC的这一临界值在112名供者中进行了前瞻性验证。发现阳性预测值为100%，而阴性预测值为17%。
XN-HPC作为一种具有成本效益且节省时间的CD34+细胞计数替代指标具有非常可观的潜力。
